

whereas CD56^{bright} cells are believed to be immunoregulatory actors (10, 11). Here, we present studies that characterize the effects of IL15 infusions on various aspects of NK-cell function in cancer patients. We show that IL15 infusions were associated with over 350-fold expansion of the CD56^{bright} NK-cell subpopulation and a 20-fold expansion of the CD56^{dim} NK subpopulation. The CD56^{bright} cells showed increased proliferation that may have been caused by higher CD122 expression. Population expansion rates were more than 10-fold higher in the CD56^{bright} subset following treatment when compared with other NK-cell subsets resulting in nearly equal numbers of both types of cells present in the peripheral blood after 10-day IL15 infusions. In addition, CD56^{bright} NK cells acquired the capability to respond to target cell activation by both increased cytokine production and cytotoxicity as a result of the treatment. These data suggest that CD56^{bright} NK cells generated by IL15 infusions have a potential to respond to tumors sensitive to NK cells.

We analyzed cytokine production of NK-cell subsets. CD56^{bright} NK cells respond to cytokine or PMA/Ionomycin stimulations with the generation of several cytokines (12, 25, 26, 29). We observed that this activity was even more pronounced after IL15 infusions. The effect could be explained by increased cytokine receptor expressions, but additional intracellular changes are likely to exist as suggested by the improved responses to PMA/Ionomycin that did not require receptor expression. In addition, cytokine generation was only observed after coinubations with NK target cells after IL15 infusions. This suggests that treatment induced expression of receptors, normally absent on CD56^{bright} NK cells, that could recognize ligands on tumor cells. In the case of antibody-coated target cells, this improved recognition may involve the Fc receptor CD16, expression of which was upregulated after IL15 infusion. IL15 treatment-induced CD56^{bright} NK cells also responded to K562 cells. The receptors that recognize this cell line appear to be more complex (27, 28) and may involve NKp30, NKp46, and NKG2D, expression of which had also been increased after IL15 infusions. Thus, multiple mechanisms are implicated in increased cytokine responses in IL15 infusion-induced CD56^{bright} NK cells.

We analyzed surface marker expression changes that were induced by IL15 infusions. We observed that changes in both subpopulations contributed to an increased phenotype similarity between them. We believe that this is most consistent with activities that were induced by higher concentrations of IL15 that had been achieved after infusions when compared with physiological steady-state levels. Such higher cytokine concentrations could have activated a signaling pathway with similar signaling strength in both cell types to result in similar expressions of some surface molecules. Infusions also caused an increase of CD62L⁻ and a decrease of CD57⁻ expressing populations among CD56^{dim} cells as well as a decrease of the CD27⁺ population among

CD56^{bright} cells, suggesting that IL15 treatments induced expansion of less mature NK-cell populations (30–34).

Many phenotypic changes that were induced by IL15 infusions are also found after IL15-induced *ex vivo* cultures of NK cells (14, 15, 35–37). These include increases of NKp30, NKp46, NKG2D, Trail, and CXCR3, and decreases of CD57, CD27, and CCR7. One exception, however, exists. Cultured NK cells typically upregulate markers of activation including CD69, CD25, NKp44, and DNAM1 (14, 15, 38). We did not observe inductions of these markers after IL15 infusions. Because bona fide activating ligands are unlikely to be induced by culturing, the discrepancy between culture and infusions is most consistent with inhibitory mechanisms *in vivo* that are lost during culturing resulting in NK-cell activation *in vitro* only. A lack of NK-cell activation in IL15-infused cancer patients also suggests that no encounters between cancer and the analyzed blood NK cells had occurred that would have caused their activation.


The relationship between CD56^{dim} and CD56^{bright} NK cells remains a matter of debate. Most publications suggest CD56^{bright} NK cells represent a developmentally precursor stage (10). Others describe the ability to derive CD56^{bright} from CD56^{dim} via NK-cell activation (39, 40). Along this line, the increased presence of CD56^{bright} NK cells following IL15 treatments could have been caused by either different expansion rates of both cell subsets or a conversion of CD56^{dim} into CD56^{bright} NK cells. Most of our findings support the former: Analyses *ex vivo* showed increased proliferation rates in the CD56^{bright} subset (Fig. 1B). In addition, *in vitro* proliferation assays point to an increased ability of CD56^{bright} NK cells to proliferate in response to IL15 (Supplementary Fig. S1). Moreover, one would expect that descendants of a recent CD56^{dim} to CD56^{bright} conversion would retain some of the phenotypical markers of their precursor cells. Most of our data appear to suggest the opposite in that the majority of surface markers that are distinct between both subsets were expressed at similar levels on CD56^{bright} NK cells before and after treatments. These include CXCR3, CX3CR1, CD16, NKG2A, and CD158b (Fig. 2; Supplementary Fig. S2). CD25 and CCR7 are exceptions in that their expressions were downregulated on posttreatment CD56^{bright} NK cells to levels similar of CD56^{dim} NK cells. In summary, our data suggest that the predominant appearance of CD56^{bright} NK cells in response to IL15 treatments resulted mainly from a superior ability of this subset to proliferate.

An issue for all NK-cell-based cancer immunotherapy targeting solid tumors is their ability to migrate from blood to tumor sites. We had analyzed the expression of several chemokine receptors whose involvement in tumor-directed migration has been reported (5, 41, 42). No clear pattern emerged. Expression of CXCR3 and CX3CR1 increased, expression of CCR7 decreased, and expression of CXCR1 remained unchanged. Further studies are necessary to delineate migration patterns of IL15 infusion-induced NK cells.

Figure 3.

IL15 infusions sensitize NK cells to respond with cytokine production. PBMCs were stimulated with PMA/Ionomycin (A), IL12/IL18 (B), or coinubated with NK target cells (C), and intracellular cytokine amounts were determined by FACS on gated CD56^{dim} (CD3⁻/CD16⁺/CD56^{dim}) or CD56^{bright} (CD3⁻/CD56^{bright}) NK cells. IL15 infusions caused increases of IFN γ , TNF α , and GM-CSF productions in PMA/Ionomycin- or IL12/IL18-responding NK cells within the CD56^{bright} subset. Within the CD56^{dim} subset, IFN γ production was increased after IL12/IL18 stimulation. CD56^{bright} NK cells also acquired the ability to respond to target cell exposure by cytokine production after IL15 infusions, whereas little change was seen for target cell-exposed CD56^{dim} NK cells. D shows that IL15 infusions had increased the expression of surface IL18 receptor on CD56^{dim} NK cells to levels lower than those on CD56^{bright} NK cells. We observed no IL12 receptor expression changes. Analyses were done once on each of 5 patients. Graphs depict mean + SD. *, $P < 0.05$ and **, $P < 0.01$.

Dubois et al.

**Figure 4.**

IL15 infusions increase cytotoxic activities in both NK-cell subsets. **A**, Intracellular stains of gated NK subsets indicate decreases of cytotoxic molecules in CD56^{dim} NK cells, whereas the amounts of granzymes A, B, and perforin increased in CD56^{bright} NK cells after IL15 infusions. **B**, IL15 infusions augmented cytolytic activities for both sorted NK-cell subsets against three different target lines. Analyses were done once on each of 5 patients. Graphs depict mean \pm SD. *, $P < 0.05$; **, $P < 0.01$; and ***, $P < 0.001$.

We observed improved cytotoxic activities for both CD56^{bright} and CD56^{dim} NK cells against diverse target cell lines with various recognition requirements. Several changes in CD56^{bright} cells that had been caused by IL15 treatments could account for this increase: Besides improved recognition of target cells, these cells had increased intracellular amounts of the molecules Granzyme A, Granzyme B, and Perforin that are used for killing target cells. This was not the case for CD56^{dim} NK cells that also showed

increased killing activities despite lower amounts of granzymes and perforin. However, increased amounts of membrane-bound death receptor ligand Trail may contribute to stronger cytotoxic responses as may the improved recognition via NKG2D for MICA-expressing targets, NKp30 and NKp46 for K562. Thus, the goal of inducing augmented cytotoxic NK-cell activities by IL15 infusions was achieved that may suggest a potential utility in cancer immunotherapy.

In summary, continuous infusions of IL15 in cancer patients is accompanied by a preferential expansion of populations of phenotypically immature CD56^{bright} NK cells with increased abilities to recognize tumor cells and react by cytokine production and cytotoxicity. On the basis of the present study, IL15, by increasing NK-cell numbers and their cytotoxic capacity, may increase the efficacy of anticancer therapies. IL15 could be useful in cases of tumors that have deleted Class I MHC where direct NK cytotoxicity may be effective. IL15 may be useful in combination with therapies that are based on antitumor antibodies of which the effects include tumor killing via ADCC. To translate this opportunity in the treatment of leukemia, we have initiated a clinical trial using IL15 with anti-CD52 alemtuzumab (NCT02689453), and we are planning to combine IL15 with anti-CCR4 mogamulizumab in patients with HTLV-1-associated adult T-cell leukemia/lymphoma (43).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: S. Dubois, J.R. Müller, T.A. Waldmann
Development of methodology: S. Dubois, J.R. Müller

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Dubois, K.C. Conlon, J. Hsu-Albert, T.A. Waldmann
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Dubois, J.R. Müller
Writing, review, and/or revision of the manuscript: S. Dubois, K.C. Conlon, J.R. Müller, T.A. Waldmann
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): N. Beltran, B.R. Bryant
Study supervision: T.A. Waldmann

Acknowledgments

We thank Dr. Groh-Spies, Fred Hutchinson Cancer Research Center, for providing the C1R-MICA cell line and Drs. Sharrow (EIB, NCI, NIH) and Livak (LGI, NCI, NIH) for cytometry and cell sortings. This study was approved by the Institutional Review Board of the NCI, NIH.

Grant Support

This study was supported by the intramural program of the NCI, NIH. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 1, 2017; revised June 28, 2017; accepted August 21, 2017; published OnlineFirst August 25, 2017.

References

- Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. *Int J Cancer* 1975; 16:230–9.
- Jondal M, Pross H. Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. *Int J Cancer* 1975;15:596–605.
- Kiessling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. *Eur J Immunol* 1975;5:117–21.
- Pross HF, Jondal M. Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes. *Clin Exp Immunol* 1975;21:226–35.
- Cantoni C, Grauwet K, Pietra G, Parodi M, Mingari MC, Maria AD, et al. Role of NK cells in immunotherapy and virotherapy of solid tumors. *Immunotherapy* 2015;7:861–82.
- Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. *J Immunol* 1986; 136:4480–6.
- Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, et al. CD56^{bright} human NK cells differentiate into CD56^{dim} cells: role of contact with peripheral fibroblasts. *J Immunol* 2007;179:89–94.
- Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. *Trends Immunol* 2013;34:573–82.
- Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, et al. CD94 surface density identifies a functional intermediary between the CD56^{bright} and CD56^{dim} human NK-cell subsets. *Blood* 2010;115:274–81.
- Chelsen JE, Lugthart G, Lankester AC, Schilham MW. Human circulating and tissue-resident CD56^(bright) natural killer cell populations. *Front Immunol* 2016;7:262.
- Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. *Trends Immunol* 2001;22:633–40.
- Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. *J Immunol* 1999;162: 4511–20.
- Nielsen N, Odum N, Urso B, Lanier LL, Spee P. Cytotoxicity of CD56 (bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. *PLoS One* 2012;7:e31959.
- Anguille S, Van Acker HH, Van den Bergh J, Willems Y, Goossens H, Van Tendeloo VF, et al. Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact- and IL-15-dependent manner. *PLoS One* 2015;10:e0123340.
- Romee R, Leong JW, Schneider SE, Sullivan RP, Fehniger TA. IL-15 primes a highly potent anti-leukemia response by CD56^{bright} NK cells. *Blood* 2013;122:2283.
- Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. *Nat Immunol* 2016;17:1025–36.
- Moretta L. Dissecting CD56^{dim} human NK cells. *Blood* 2010;116: 3689–91.
- Orr MT, Lanier LL. Natural killer cell education and tolerance. *Cell* 2010; 142:847–56.
- Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. *J Exp Med* 2000;191:771–80.
- Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44^{high} T cells and its antitumor action. *J Immunol* 2008;180:2099–106.
- Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. *Immunity* 2007;26:503–17.
- Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, et al. Augmented IL-15Ralpha expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. *J Immunol* 2012;188:6156–64.
- Zhang M, Yao Z, Dubois S, Ju W, Muller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. *Proc Natl Acad Sci U S A* 2009;106:7513–8.
- Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. *J Clin Oncol* 2015;33:74–82.
- Barakonyi A, Rabot M, Marie-Cardine A, Aguerre-Girr M, Polgar B, Schiavon V, et al. Cutting edge: engagement of CD160 by its HLA-C

Dubois et al.

- physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. *J Immunol* 2004;173:5349–54.
26. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. *Blood* 2010;115:2167–76.
 27. Bae DS, Hwang YK, Lee JK. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. *Cell Immunol* 2012;276:122–7.
 28. Mavoungou E, Bouyou-Akotet MK, Kremsner PG. Effects of prolactin and cortisol on natural killer (NK) cell surface expression and function of human natural cytotoxicity receptors (NKp46, NKp44 and NKp30). *Clin Exp Immunol* 2005;139:287–96.
 29. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaehri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. *Blood* 2001;97:3146–51.
 30. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. *Blood* 2010;116:3853–64.
 31. Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. *Blood* 2010;116:1299–307.
 32. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. *Blood* 2010;116:3865–74.
 33. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. *J Immunol* 1989;143:3183–91.
 34. Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, et al. CD27 defines phenotypically and functionally different human NK cell subsets. *J Immunol* 2008;180:3739–45.
 35. Lum JJ, Schnepfle DJ, Nie Z, Sanchez-Dardon J, Mbisa GL, Mihowich J, et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. *J Virol* 2004;78:6033–42.
 36. Moustaki A, Argyropoulos KV, Baxevasis CN, Papamichail M, Perez SA. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function. *Cancer Immunol Immunother* 2011;60:1683–95.
 37. Vukicevic M, Chalandon Y, Helg C, Matthes T, Dantin C, Huard B, et al. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. *Eur J Immunol* 2010;40:3246–54.
 38. Hromadnikova I, Pirkova P, Sedlackova L. Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors. *Mediators Inflamm* 2013;2013:405295.
 39. Loza MJ, Perussia B. The IL-12 signature: NK cell terminal CD56+high stage and effector functions. *J Immunol* 2004;172:88–96.
 40. Muller JR, Waldmann TA, Dubois S. Loss of cytotoxicity and gain of cytokine production in murine tumor-activated NK cells. *PLoS One* 2014;9:e102793.
 41. Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. *J Surg Oncol* 2012;106:386–92.
 42. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. *Cancer Res* 2008;68:8437–45.
 43. Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. *J Exp Med* 2014;211:2497–505.

Cancer Immunology Research

IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56^{bright} NK Cells and Increases NK-Cell Cytokine Release Capabilities

Sigrid Dubois, Kevin C. Conlon, Jürgen R. Müller, et al.

Cancer Immunol Res 2017;5:929-938. Published OnlineFirst August 25, 2017.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-17-0279](https://doi.org/10.1158/2326-6066.CIR-17-0279)

Supplementary Material Access the most recent supplemental material at:
<http://cancerimmunolres.aacrjournals.org/content/suppl/2017/08/26/2326-6066.CIR-17-0279.DC1>

Cited articles This article cites 43 articles, 23 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/5/10/929.full#ref-list-1>

Citing articles This article has been cited by 8 HighWire-hosted articles. Access the articles at:
<http://cancerimmunolres.aacrjournals.org/content/5/10/929.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/5/10/929>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.